{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:34Z","timestamp":1790837194867,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EUSA Pharma (UK) Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12325-019-01167-2","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T12:05:02Z","timestamp":1576325102000},"page":"730-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Kirsi M.","family":"Manz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fenchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Eilers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Wittling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7683-1017","authenticated-orcid":false,"given":"Wolfram C. M.","family":"Dempke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,14]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056","author":"B Escudier","year":"2019","unstructured":"Escudier B, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz056.","journal-title":"Ann Oncol"},{"key":"1167_CR2","unstructured":"Ljungberg B, Albiges L, Bensalah K, Bex A. EAU-RCC-Guidelines-2018-large-text.pdf. 2018. https:\/\/uroweb.org\/wp-content\/uploads\/EAU-RCC-Guidelines-2018-large-text.pdf. Accessed 11 Apr 2019."},{"key":"1167_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1586\/era.13.40","volume":"13","author":"HH Wong","year":"2013","unstructured":"Wong HH, Eisen T. Tivozanib for the treatment of metastatic renal cancer. Expert Rev Anticancer Ther. 2013;13:649\u201360.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","volume":"13","author":"P Bhargava","year":"2011","unstructured":"Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13:103\u201311.","journal-title":"Curr Oncol Rep"},{"key":"1167_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.eururo.2018.03.036","volume":"74","author":"CJD Wallis","year":"2018","unstructured":"Wallis CJD, Klaassen Z, Bhindi B, et al. First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol. 2018;74:309\u201321.","journal-title":"Eur Urol"},{"key":"1167_CR6","doi-asserted-by":"crossref","first-page":"15801","DOI":"10.18632\/oncotarget.7511","volume":"7","author":"X Chang","year":"2016","unstructured":"Chang X, Zhang F, Liu T, et al. Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget. 2016;7:15801\u201310.","journal-title":"Oncotarget"},{"key":"1167_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:65\u201394.","journal-title":"Ann Intern Med"},{"key":"1167_CR8","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1167_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2288-10-54","volume":"10","author":"BS Woods","year":"2010","unstructured":"Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10:54.","journal-title":"BMC Med Res Methodol"},{"key":"1167_CR10","doi-asserted-by":"publisher","first-page":"d2090","DOI":"10.1136\/bmj.d2090","volume":"343","author":"DG Altman","year":"2011","unstructured":"Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011;343:d2090.","journal-title":"BMJ"},{"key":"1167_CR11","unstructured":"R\u00fccker G, Krahn U, K\u00f6nig J, Efthimiou U, Schwarzer G. Netmeta: network meta-analysis using frequentist methods. R package version 1.0-1. 2019. https:\/\/CRAN.R-project.org\/package=netmeta."},{"key":"1167_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-analysis with R","author":"G Schwarzer","year":"2015","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker TG. Meta-analysis with R. New York: Springer International Publishing; 2015."},{"key":"1167_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","volume":"13","author":"U Krahn","year":"2013","unstructured":"Krahn U, Binder H, K\u00f6nig J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13:35.","journal-title":"BMC Med Res Methodol"},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3:312\u201324.","journal-title":"Res Synth Methods"},{"key":"1167_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"Laird N DerSimonianR","year":"1986","unstructured":"DerSimonianR Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1167_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/096228029300200202","volume":"2","author":"JL Fleiss","year":"1993","unstructured":"Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121\u201345.","journal-title":"Stat Methods Med Res"},{"key":"1167_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2011","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2011;15:58.","journal-title":"BMC Med Res Methodol"},{"key":"1167_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061\u20138.","journal-title":"J Clin Oncol"},{"key":"1167_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med"},{"key":"1167_CR20","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1200\/JCO.2011.35.3524","volume":"30","author":"DA Nosov","year":"2012","unstructured":"Nosov DA, Nosov D, Eisen T, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol. 2012;30:1678\u201385.","journal-title":"J Clin Oncol"},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Nosov D, Eisen T, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280\u20139.","journal-title":"J Clin Oncol"},{"key":"1167_CR22","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","volume":"31","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31:3791\u20139.","journal-title":"J Clin Oncol"},{"key":"1167_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35:591\u20137.","journal-title":"J Clin Oncol"},{"key":"1167_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:22\u201331.","journal-title":"N Engl J Med"},{"key":"1167_CR25","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","volume":"26","author":"JL Lee","year":"2015","unstructured":"Lee JL, Kim MK, Park I, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300\u20135.","journal-title":"Ann Oncol"},{"key":"1167_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","volume":"68","author":"C Eichelberg","year":"2015","unstructured":"Eichelberg C, Bedke J, B\u00f6gemann M, et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell carcinoma. Eur Urol. 2015;68:837\u201347.","journal-title":"Eur Urol"},{"key":"1167_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2018.11.001","volume":"107","author":"M Retz","year":"1990","unstructured":"Retz M, Bedke J, B\u00f6gemann M, et al. SWITCH II: phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11). Eur J Cancer. 1990;107:37\u201345.","journal-title":"Eur J Cancer"},{"key":"1167_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1200\/jco.2014.32.4_suppl.502","volume":"32","author":"Y Tomita","year":"2017","unstructured":"Tomita Y, Naito S, Sassa N, et al. Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: a multicenter randomized trial, CROSS-J-RCC. J Clin Oncol. 2017;32:502\u201310.","journal-title":"J Clin Oncol"},{"key":"1167_CR29","doi-asserted-by":"publisher","first-page":"LBA308","DOI":"10.1200\/jco.2011.29.7_suppl.lba308","volume":"29","author":"RJ Motzer","year":"2011","unstructured":"Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4\/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal Effect Trial. J Clin Oncol. 2011;29:LBA308.","journal-title":"J Clin Oncol"},{"key":"1167_CR30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","volume":"30","author":"RJ Motzer","year":"2012","unstructured":"Motzer RJ, Plimack ER, Ernstoff MS, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30:1371\u20137.","journal-title":"J Clin Oncol"},{"key":"1167_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","volume":"6","author":"A Amin","year":"2018","unstructured":"Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109\u201315.","journal-title":"J Immunother Cancer."},{"key":"1167_CR32","unstructured":"ClinicalTrials.gov. Phase 1\/2 Study of tivozanib in combination with nivolumab in subjects with RCC\u2014Full Text View\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03136627. Accessed 23 May 2019."},{"key":"1167_CR33","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DV, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370\u201385.","journal-title":"Lancet Oncol."},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103\u201315.","journal-title":"N Engl J Med"},{"key":"1167_CR35","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus R, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116\u201327.","journal-title":"N Engl J Med"},{"key":"1167_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.09.002","author":"AW Hahn","year":"2019","unstructured":"Hahn AW, Klaasen Z, Agarwal N, et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2019. https:\/\/doi.org\/10.1016\/j.euo.2019.09.002.","journal-title":"Eur Urol Oncol."},{"key":"1167_CR37","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/cncr.25750","volume":"117","author":"DYC Heng","year":"2011","unstructured":"Heng DYC, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011;117:2637\u201342.","journal-title":"Cancer."},{"key":"1167_CR38","unstructured":"Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2019. http:\/\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. Accessed 23 May 2019."},{"key":"1167_CR39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","volume":"49","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49:1287\u201396.","journal-title":"Eur J Cancer"},{"key":"1167_CR40","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584\u201390.","journal-title":"J Clin Oncol"},{"key":"1167_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2017.35.6_suppl.469","volume":"35","author":"Y Tomita","year":"2017","unstructured":"Tomita Y, Fukasawa S, Shinohara N, et al. Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: a multicenter randomized trial, CROSS-J-RCC. J Clin Oncol. 2017;35:469\u201374.","journal-title":"J Clin Oncol."},{"issue":"Suppl 2","key":"1167_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1634\/theoncologist.2011-S2-32","volume":"16","author":"A Ravaud","year":"2011","unstructured":"Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16(Suppl 2):32\u201344.","journal-title":"Oncologist"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01167-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T00:05:51Z","timestamp":1607817951000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01167-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,14]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01167-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,14]]},"assertion":[{"value":"30 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}